Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Apr;5(2):354-363.
doi: 10.1002/ehf2.12249. Epub 2018 Jan 17.

The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling

Kyungil Park  1 , Young-Dae Kim  1 , Ki-Sik Kim  2 , Su-Hoon Lee  3 , Tae-Ho Park  1 , Sang-Gon Lee  4 , Byung-Soo Kim  5 , Seung-Ho Hur  6 , Tae-Hyun Yang  7 , Joo-Hyun Oh  8 , Taek-Jong Hong  9 , Jong-Sun Park  10 , Jin-Yong Hwang  11 , Byungcheon Jeong  12 , Woo-Hyung Bae  13 ; VALID Investigators
Affiliations
Randomized Controlled Trial

The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling

Kyungil Park et al. ESC Heart Fail. 2018 Apr.

Abstract

Aims: Although clinical guidelines advocate the use of the highest tolerated dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after acute myocardial infarction (MI), the optimal dosing or the risk-benefit profile of different doses have not been fully identified.

Methods and results: In this multicentre trial, 495 Korean patients with acute ST segment elevation MI and subnormal left ventricular (LV) ejection fraction (<50%) were randomly allocated (2:1) to receive maximal tolerated dose of valsartan (titrated up to 320 mg/day, n = 333) or low-dose valsartan (80 mg/day, n = 162) treatment. The primary objective was to assess the changes in echocardiographic parameters of LV remodelling from baseline to 12 months after discharge. After treatment, end-diastolic LV volume (LVEDV) decreased significantly in the low-dose group, but the difference in LVEDV changes was insignificant between the maximal-tolerated-dose and low-dose groups. End-systolic LV volume decreased significantly in both groups, to a similar degree between groups. LV ejection fraction rose significantly in both study groups, to a similar degree. Changes in plasma levels of neurohormones were also comparable between the two groups. Drug-related adverse effects occurred more frequently in the maximal-tolerated-dose group than in the low-dose group (7.96 vs. 0.69%, P < 0.001).

Conclusions: In the present study, treatment with the maximal tolerated dose of valsartan did not exhibit a superior effect on post-MI LV remodelling compared with low-dose treatment and was associated with a greater frequency of adverse effect in Korean patients. Further study with a sufficient number of cases and statistical power is warranted to verify the findings of the present study.

Keywords: Dose; Myocardial infarction; Valsartan; Ventricular remodelling.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of participants in the randomized controlled trial. Five hundred four patients were enrolled at 17 centres and assessed for eligibility. Of those enrolled, nine were excluded from randomization for screening failure. Four hundred ninety‐five patients were randomized, of which 333 were allocated to the maximal‐tolerated‐dose group and 162 patients were allocated to the low‐dose group.
Figure 2
Figure 2
Systolic and diastolic blood pressure in the two treatment groups over the course of the trial.
Figure 3
Figure 3
Effect of valsartan on left ventricular echocardiographic measurements. Changes in left ventricular end‐diastolic volume (A), end‐systolic volume (B), and ejection fraction (C) from baseline to 12 months after randomization in both groups.
Figure 4
Figure 4
Effect of valsartan on plasma neurohormones. Changes in plasma B‐type natriuretic peptide (A) and norepinephrine (B) from baseline to 12 months after randomization.
See this image and copyright information in PMC

References

    1. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta‐analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598–604. - PubMed
    1. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators . Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–677. - PubMed
    1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators . Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828. - PubMed
    1. Kober L, Trop‐Pedersen C, Carisen JE, Bagger H, Eliasen P, Lyngborg K, Videbek J, Cole DS, Auclert L, Pauly N, Aliot E, Persson S, Camm AJ, Trandolapril Cardiac Evaluation (TRACE) Study Group . A clinical trial of the angiotensin‐converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1676. - PubMed
    1. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources